my personal edition > dermatology other > news
E-Mail this DGNews to a colleague
DGNews
Dusa Pharmaceuticals Reports Brazilian Regulatory Approval for Levulan (Aminolevulinic Acid Hcl) Topical Solution
Product Launch Expected by Early '07
WILMINGTON, MA -- October 17, 2006 -- DUSA Pharmaceuticals, Inc. today reported that Stiefel Laboratories, Inc., DUSA's marketing partner for Latin America, has been informed by ANVISA, the Brazilian drug regulatory authorities, that the Levulan® Kerastick® (aminolevulinic acid Hcl) topical solution has been approved in Brazil. With DUSA's support, Stiefel Laboratories completed the regulatory filing with ANVISA during the second quarter of this year.
Robert Doman, DUSA's President and COO, stated "We are very pleased with the joint efforts between the two companies and progress that has been made since the signing of our agreement with Stiefel Laboratories in January. This represents a significant step in our goal of expanding the distribution of Levulan PDT beyond the North American market."
Additional launches are expected to follow in a number of other Latin American countries, subject to regulatory approvals.
In January 2006, DUSA Pharmaceuticals, Inc. announced that it entered into an exclusive marketing, distribution and supply agreement for Latin America with Stiefel Laboratories, Inc. The agreement covers current and future uses of DUSA's proprietary Levulan ® Kerastick ® for photodynamic therapy (PDT) in dermatology.
SOURCE: DUSA Pharmaceuticals, Inc.
All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.
| 
